Finding no magic for 'Merlin,' Sir Evans shifts focus

Sir Christopher Evans' is scrapping Merlin Biosciences and transferring the early-stage venture funds to the newly-formed Excalibur, which will shift focus to late-stage therapies. That's bitter news to start-ups in the UK, which have long been able to tap into the seed funds offered by Merlin. Evans plans to raise a new fund with £100 million to invest in a range of companies spanning everything from specialty pharma to surgical equipment makers.

Many early-stage biotechs are "fraught with difficulty" and may have to consolidate, Evans told the Financial Times. Merlin's three funds are worth more than £450 million.

- read the article in the Financial Times

Related Articles:
Tips for funding a biotech start-up. Report
VC firm looks to early-stage research projects. Report

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.